

April 4, 2014

Dainippon Sumitomo Pharma Co., Ltd.

## **Dainippon Sumitomo Pharma Announces Revisions to Its Financial Forecasts for the Year Ended March 31, 2014**

Osaka, Japan, April 4, 2014 - Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; Securities Codes: 4506, First Section of TSE) announced today that it has revised its financial forecasts for the fiscal year 2013 as summarized below, in light of recent performance trends and other factors.

1. Revisions to the Forecasts of Consolidated Financial Results for the Fiscal Year 2013 (April 1, 2013 to March 31, 2014)

(Amounts in Japanese yen million, unless otherwise specified)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
Previous Forecasts (A)	385,000	35,000	34,000	17,000	¥42.79
Revised Forecasts (B)	387,000	42,000	41,000	20,000	¥50.34
Variance in amount (B) – (A)	2,000	7,000	7,000	3,000	
Variance in percent (%)	0.5	20.0	20.6	17.6	
[Reference] Previous year (Year ended March 31, 2013)	347,724	25,043	24,505	10,043	¥25.28

2. Reasons for the revisions

The net sales are now forecasted to exceed the previously-announced forecast, reflecting the brisk sales in the “North America” segment.

SG&A expenses less R&D costs meanwhile are expected to be lower than the forecast due mainly to the efforts for effective control of expenses, and R&D costs are also expected to decrease from the forecast due largely to delay of incurring.

With regard to extraordinary loss, impairment loss is expected to be posted in addition.

Consequently, the Company now forecasts that net sales for the fiscal year 2013 will increase by 2,000 million yen to 387,000 million yen, operating income will increase by 7,000 million yen to 42,000 million yen, ordinary income will increase by 7,000 million yen to 41,000 million yen and net income will increase by 3,000 million yen to 20,000 million yen, all from the previously-announced respective forecasts.

### Cautionary statement:

Forecasts shown above are based on management’s assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.

### Contact:

Corporate Communications

Dainippon Sumitomo Pharma

TEL: +81-6-6203-1407 (Osaka)

+81-3-5159-3300 (Tokyo)